Highlights of This Issue   6333

SPECIAL FEATURES

CCR Translations

6335 The Role of Protein Kinase CK2 in Glioblastoma Development Haitao Ji and Zhimin Lu
See related article, p. 6484

CCR New Strategies

6338 New Strategies in Radiation Therapy: Exploiting the Full Potential of Protons Radhie Mohan, Anita Mahajan, and Bruce D. Minsky

Molecular Pathways

6344 Molecular Pathways: Protein Methyltransferases in Cancer Robert A. Copeland

CCR Focus

6352 On Masterpieces and Breast Cancer Research Susan E. Bates
6353 Progress in Breast Cancer: Overview Carlos L. Arteaga
6360 Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer Aditya Bardia and José Baselga
6371 Incorporating Genomics into Breast Cancer Clinical Trials and Care Adel Tabechy, Cynthia X. Ma, Ron Bose, and Matthew J. Ellis
6380 Tackling the Diversity of Triple-Negative Breast Cancer Nicholas C. Turner and Jorge S. Reis-Filho
6389 Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer Xiang H.-F. Zhang, Mario Giuliano, Meghana V. Trivedi, Rachel Schiff, and C. Kent Osborne
6398 Can Immunity to Breast Cancer Eliminate Residual Micrometastases? Mary L. Disis and Sasha E. Stanton

HUMAN CANCER BIOLOGY

6419 JMJ2B Promotes Epithelial–Mesenchymal Transition by Cooperating with β-Catenin and Enhances Gastric Cancer Metastasis Ji Zhao, Wenjuan Li, Wen Zang, Zhifang Liu, Xia Xu, Han Yu, Qing Yang, and Jihui Jia


Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer Takeshi Iwaya, Takeo Fukagawa, Yutaaka Suzuki, Yunuke Takahashi, Genta Sawada, Masahisa Ishihashi, Junji Kurashige, Tomoya Sudo, Fumiaiki Tanaka, Kohei Shibata, Fumitaka Endo, Hirokatsu Katagiri, Kaoru Ishida, Kohei Kume, Satoshi Nishizuka, Hisae Inuma, Go Wakabayashi, Masaki Mori, Mitsuru Sasaki, and Koshi Mimori

PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival Hazel A. Rogers, Cerys Mayne, Rebecca J. Chapman, John-Paul Kilday, Beth Coyle, and Richard G. Grundy


Contents
Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma

Shih-Chi Su, Xiaoxiao Hu, Patrick A. Kenney, Megan M. Merrill, Kara N. Babaian, Xiu-Ying Zhang, Tapatí Maití, Shun-Fa Yang, Xin Lin, and Christopher G. Wood

Cidofovir: A Novel Antitumor Agent for Glioblastoma

Piotr Hadaczek, Tomoko Ozawa, Liliana Soroceanu, Yasuyuki Yoshida, Lisa Matlaf, Eric Singer, Estefania Fiallos, C. David James, and Charles S. Cobbs

Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma

Ying Zheng, Braden C. McFarland, Denis Drygin, Hao Yu, Susan L. Bellis, Hyunsoo Kim, Markus Bredel, and Etty N. Benveniste


Shuya Yano, Hiroshi Tazawa, Yuuri Hashimoto, Yasuhiro Shirakawa, Shinji Kuroda, Masahiko Nishizaki, Hiroyuki Nagasaka, Yasuhiro Urata, Shunsuke Kagawa, Robert M. Hoffman, and Toshiyoshi Fujiwara

Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models

Scott Portwood, Deepika Lal, Yung-Chun Hsu, Rodrigo Vargas, Megan K. Johnson, Meir Wetzler, Charles P. Hart, and Eunice S. Wang

The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low H3K9 Expression

Marion A. Salvador, Julien Wicinski, Olivier Cabaud, Yves Toiron, Pascal Finetti, Emmanuelle Josselin, Hélène Le Lièvre, Laurence Kraus-Berthier, Stéphane Depil, François Bertucci, Yves Collette, Daniel Birnbaum, Emmanuelle Charaf-Jauffret, and Christophe Ginestier

Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

Tao Liu, Wei Hu, Heather J. Dalton, Huyin Jin Choi, Jie Huang, Yu Kang, Sunila Pradeep, Takahito Miyake, Jian H. Song, Yunfei Wen, Chunhua Lu, Chad V. Pecot, Justin Bottsford-Miller, Behrouz Zand, Nicholas B. Jennings, Cristina Ivan, Gary E. Gallick, Keith A. Buggerly, David G. Hargauer, Robert L. Coleman, Michael Frumovitz, and Anil K. Sood

Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer


EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma


End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis

Junhee Pyo, Kyung Won Kim, Heather A. Jacene, Christopher G. Sakellis, Jennifer R. Brown, and Annick D. Van den Abbeele

A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Study (ADVL1112)

Patrick A. Thompson, Rachid Drissi, Jodi A. Muscal, Eshini Panditharatna, Maryam Fouladi, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Tong Lin, Brenda J. Weigel, and Susan M. Blaney
Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer

Patrick J. Schuler, Malgorzata Harasymczuk, Bastian Schilling, Zenichiro Saze, Laura Strauss, Stephan Lang, Jonas T. Johnson, and Theresa L. Whiteside

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)

Ronald S. Go, Sandra J. Lee, Donghoon Shin, Steven M. Callister, Dean A. Jobe, Robert M. Conry, Ahmad A. Tarihi, and John M. Kirkwood

Photodynamic Therapy with 3-(1'-Hexyloxyethyl) Pyropheophorbide a for Cancer of the Oral Cavity

Nestor Rigual, Gal Shafirstein, Michele T. Cooper, Heinz Baumann, David A. Bellnier, Ulas Sunar, Erin C. Tracy, Daniel J. Rohrbach, Gregory Wilding, Wei Tan, Maureen Sullivan, Mihai Merzianu, and Barbara W. Henderson

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Andrew X. Zhu, Richard S. Finn, Mary Mulcahy, Jayne Gurtler, Weijing Sun, Jonathan D. Schwartz, Rita P. Dalal, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Marek Ancukiewicz, Rakesh K. Jain, Francis W. Nugent, Dan G. Duda, and Keith Stuart

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab


Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers

Ranee Mehra, Fang Zhu, Dong-Hua Yang, Kathy Q. Cui, JoEllen Weaver, Mahendra K. Singh, Anna S. Nikonova, Erica A. Golemis, Douglas B. Flieder, Harry S. Cooper, Miriam Lango, John A. Ridge, and Barbara Burtness

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a human U251-MG glioblastoma cell transfected with 100 nM of non-target siRNA. Phalloidin (green) and DAPI (blue) staining shows organized F-actin and cell morphology. For details, see the article by Zheng and colleagues on page 6484 of this issue.